Finding high‑quality growth stocks under $50 is not easy in today’s market. Using the TipRanks Stock Screener, we have identified three stocks with strong long‑term potential at a reasonable price. From next-generation fintech to fast-growing athletic apparel and breakthrough biotech, these three stocks combine compelling fundamentals with catalysts that could drive meaningful upside.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
1. On Holdings (ONON)
On Holdings, the Swiss performance-footwear company, continues to post strong revenue growth as it expands globally. The brand has built a loyal customer base, supported by premium pricing power and a steady stream of new products in running, training, and apparel.
With rapid growth in North America and Europe, strong direct-to-consumer momentum, and rising visibility through athlete partnerships and retail expansion, the company has a long runway ahead. Its combination of brand strength and category expansion makes it a key consumer growth stock still trading under $50.
Last week, Telsey Advisory kept a Buy rating on the stock. The firm believes the company remains on a solid growth path driven by product innovation, steady store openings, rising apparel penetration, new market expansion, and ongoing marketing efforts.
Wall Street’s consensus rating for ONON stock is a Strong Buy based on 16 Buys, one Hold, and one Sell. The average analyst price target of $56.67 implies an upside potential of 71.47% from current levels.
2. Figure Technology Solutions (FIGR)
Figure is building a modern fintech platform that uses blockchain to make lending, loan servicing, and capital markets processes faster and more efficient. Its Provenance blockchain helps cut costs and speed up settlement, giving financial institutions a cleaner, more streamlined alternative to traditional systems.
As more firms upgrade their infrastructure, FIGR could see rising demand and remains an appealing under‑$50 stock pick.
Bernstein analyst Gautam Chhugani said FIGR stock remains an Outperform even after lowering the price target to $67. He argued that weak crypto sentiment and geopolitics are creating rare discounts in companies tied to massive long‑term, trillion‑dollar markets.
On TipRanks, analysts have a Strong Buy consensus rating on Figure stock based on seven Buys and one Sell assigned in the past three months. Further, the average Figure stock price target of $57.50 per share implies 66.67% upside potential.
3. Viking Therapeutics (VKTX)
Viking Therapeutics has become a closely watched small-cap biotech thanks to its promising obesity and metabolic‑disease pipeline. Its GLP‑1 and dual‑agonist drug candidates have shown strong early-stage results, putting Viking in the mix of the fast‑growing weight‑loss drug market.
As obesity treatments continue to dominate healthcare investing, VKTX stands out as a high‑potential stock under $50.
H.C. Wainwright’s Joseph Pantginis reiterated his Buy rating on Viking stock, citing strong enrollment in both Phase 3 VANQUISH trials and growing confidence in VK2735’s late-stage data, which he believes could position the drug for U.S. approval and broad commercial uptake.
Turning to Wall Street, VKTX stock has a Strong Buy consensus rating based on 12 Buys assigned in the last three months. At $87.56, the average Viking stock price target implies upside potential of 156.32%.
